Date Published
Country
Source
Tags
- 2020 (21)
- AARP (3)
- ACA (3)
- Active-Pharmaceutical-Ingredients (2)
- Addiction (22)
- Alzheimer's (3)
- Amazon (2)
- Anti-bodies (2)
- Anti-Competition (3)
- Anti-Depressants (2)
- Anti-Trust (13)
- Anti-Vaccines (9)
- Anti-Vaxxers (9)
- Antibiotic-Resistance (2)
- Antibiotics (9)
- Antibodies (4)
- Antivirals (2)
- API (3)
- Artificial-Intelligence (2)
- Bacillus-Calmette-Guerin-Vaccine (2)
- Bankruptcies (2)
- BCG-Vaccine (4)
- Bernie-Sanders (14)
- Biden (20)
- Bill-Gates (4)
- Biohackers (5)
- Biologics (5)
- Biosimilars (8)
- Biotechnology (14)
- Black-Market (2)
- Brexit (5)
- Bulk-Buying (5)
- Burden-of-Illness (2)
- Business-Ethics (14)
- Business-Intelligence (28)
- Buyers-Club (2)
- Cancer (74)
- Cancer-Pricing (5)
- Cancer-Reimbursement (4)
- CAR-T (3)
- Carcinogens (2)
- CDC (4)
- CF (7)
- Chemotherapy (4)
- Chloroquine (2)
- Clinical-Trials (6)
- CMS (2)
- Co-Insurance (2)
- Co-Pays (6)
- Code-of-Conduct (21)
- Combination-Based-Pricing (2)
- Comparative-Effectiveness (7)
- Competition (29)
- Complex-Generics (2)
- Confidence-Levels (3)
- Congress (14)
- Congressional-Hearing (14)
- Copay-Clawback (2)
- Coronavirus (212)
- Coronavirus-Task-Force (8)
- Coronavirus-Testing (12)
- Coronavirus-Treatment (199)
- Coronavirus-Vaccine (373)
- Corporate-Conduct (2)
- Cost-Effectiveness (8)
- Covax (2)
- COVID-19 (360)
- COVID-Relief (4)
- COVID-Strain (9)
- COVID-Variant (3)
- Criminal-Investigations (4)
- Cross-Border (11)
- Cystic-Fibrosis (13)
- Daraprim (17)
- Depression (3)
- Dexamethasone (9)
- Diabetes (34)
- Disclosure (5)
- Distribution-of-Drugs (5)
- DNA (2)
- DOJ (2)
- Drug-Addiction (2)
- Drug-Approvals (3)
- Drug-Costs (125)
- Drug-Coverage (8)
- Drug-Development (22)
- Drug-Discounts (6)
- Drug-Discovery (20)
- Drug-Efficacy (3)
- Drug-Expenditures (2)
- Drug-Importation (20)
- Drug-Innovation (22)
- Drug-Manufacturing (16)
- Drug-Overdose (29)
- Drug-Prices (318)
- Drug-Pricing (444)
- Drug-Rebates (24)
- Drug-Recalls (4)
- Drug-Resistance (6)
- Drug-Shortage (16)
- Drug-Spending (2)
- Drug-Supply (12)
- Drug-Waste (3)
- DTC (28)
- Ebola (2)
- Elections (19)
- Emerging-Markets (36)
- Epidemics (6)
- Epidemiology (6)
- EpiPen (13)
- EU-Commission (4)
- EU-Policy (7)
- EU-Politics (4)
- Evergreening (3)
- Excessive-Pricing (3)
- Executive-Order (24)
- External-Reference-Pricing (6)
- Fair-Price (2)
- Favourite-Nations-Clause (2)
- FDA (23)
- FDA-Approvals (3)
- FDA-Warning (3)
- fentanyl (13)
- Financial-Toxicity (2)
- Flu (2)
- Formulary-Decision-Making (15)
- Fraud (3)
- Fraud-Settlements (3)
- G7-Countries (2)
- Gag-Clauses (2)
- Gag-Rules (2)
- Gates-Foundation (4)
- Gavi-Vaccine-Alliance (5)
- Gene-Therapy (14)
- Generic-Insulin (2)
- Generics (64)
- Global-Public-Good (2)
- Glybera (2)
- H.R._3 (8)
- Hacking (4)
- HCV (6)
- HCV-Pricing (8)
- Health-Coverage (4)
- Health-Economics (15)
- Health-Insurance (4)
- Health-Policy (3)
- Health-Systems (23)
- Health-Technology-Assessment (28)
- Healthcare-Costs (15)
- Healthcare-Expenditures (10)
- Healthcare-Premiums (2)
- Healthcare-Pricing (5)
- Hepatitis-C (15)
- Heroin (4)
- HHS (15)
- HIV (2)
- HIV-AIDS (15)
- HIV-Pricing (5)
- Hospital-Pricing (7)
- Hospitalizations (3)
- Hospitals (6)
- House-Hearing (6)
- HTA (9)
- Hydroxychloroquine (10)
- ICER (9)
- Illegal-Drugs (2)
- Immunotherapy (2)
- Indicated-Based-Pricing (2)
- Infectious-Diseases (11)
- Innovation (4)
- Insulin (115)
- Insulin-Bills (5)
- Insulin-Pricing (61)
- Insulin-Rationing (36)
- Insurance-Caps (2)
- International-Comparisons (13)
- International-Pricing-Index (5)
- International-Pricing-Referencing (12)
- Investments (10)
- Investor-Relations (3)
- Kick-Backs (10)
- Know-the-Lowest-Price-Act (11)
- Launch-Pricing (5)
- Lawsuit-Settlements (15)
- Lawsuits-Litigations (55)
- List-Prices (20)
- Lobbying (6)
- Lupus (3)
- Malaria (7)
- Mandatory-Cuts (5)
- Marijuana (2)
- Market-Access (40)
- Market-Exclusivity (5)
- Market-Intelligence (30)
- McKinsey (2)
- Measles (2)
- Mediator (2)
- Medicaid (4)
- Medical-Devices (5)
- Medical-Ethics (6)
- Medical-History (4)
- Medical-Implants (5)
- Medical-Innovation (2)
- Medical-Marketing (7)
- Medical-Supplies (2)
- Medicare (20)
- Medicare-for-all (13)
- Medicare-Negotiations (9)
- Mental-Ilness (5)
- Mergers-Acqusitions (6)
- Midterms (6)
- Migraine (3)
- Monoclonal-Antibodies (2)
- Most-Favoured-Nation (7)
- mRNA-Vaccines (2)
- MS (2)
- MSF (2)
- Multiple-Sclerosis (3)
- NAFTA (8)
- Naloxone (4)
- National-Pharmacare (13)
- National-Strategy (2)
- Neglected-Diseases (2)
- Net-Prices (2)
- Netflix-Model (7)
- NHS (31)
- NICE (19)
- NIH (2)
- Obamacare (9)
- OECD (2)
- Off-Label (5)
- Off-Patent (3)
- Opioids (161)
- Orkambi (4)
- Orphan-Drugs (20)
- Out-of-Pocket (7)
- OxyContin (29)
- Pain-killers (2)
- Pandemics (9)
- Panic-Buying (3)
- Parallel-Trade (2)
- Patent-Protection (19)
- Patent-System-Reform (2)
- Patents (11)
- Patient-Access (178)
- Patient-Advocacy (4)
- Patient-Affordability (23)
- Patient-Costs (4)
- patient-outcomes (5)
- Patient-Safety (13)
- Patients-Right-to-Know-Drug-Prices-Act (2)
- Pay-for-Delay (4)
- Pay-For-Performance (5)
- Payments (2)
- PBM-Pricing (2)
- PBMs (28)
- PBS (3)
- Pediatric-Cancers (2)
- Penalties-Fines (4)
- Personal-Importation (20)
- Pharma-Bro (4)
- Pharma-Influence (10)
- Pharmaceutical-Middlemen (2)
- Pharmaceuticals (6)
- Pharmacists (4)
- Pharmacoeconomics (4)
- Pharmacy-Benefits-Managers (43)
- Pharmacy-Chains (2)
- x Plans-for-Kids (1)
- PMPRB (9)
- Policy (3)
- Polio (3)
- Precision-Medicine (2)
- Presidential-Race (11)
- Price-Caps (4)
- Price-Controls (17)
- Price-Cuts (9)
- Price-Fixing (10)
- Price-gouging (30)
- Price-Hikes (92)
- Price-Increases (44)
- Price-Inflation (4)
- Price-Negotiations (13)
- Price-Regulations (22)
- Price-Transparency (30)
- Pricing-Bills (29)
- Pricing-Blueprint (24)
- Pricing-Board (3)
- Pricing-Caps (10)
- Pricing-Complaints (2)
- Pricing-Legislation (49)
- Pricing-Models (2)
- Pricing-Negotiations (3)
- Pricing-Reform (10)
- Pricing_Collusion (9)
- Prior-Approvals (2)
- Prior-Authorization (3)
- Procurement-Lists (2)
- Production-Logistics (13)
- Productivity (2)
- Profiteering (3)
- Profits-Revenues (3)
- Provincial-Access (3)
- Public-Funding (5)
- Public-Health (47)
- Public-Opinion (12)
- Public-Policy (4)
- Public-Trust (11)
- Purdue-Pharma (40)
- QALYs (2)
- Quality-Control (2)
- R&D (14)
- Rare-Diseases (26)
- Real-World-Data (4)
- Real-World-Evidence (6)
- Reference-Pricing (9)
- Regulatory-Affairs (4)
- Reimbursement (7)
- Reimportation (5)
- Relief-Bill (3)
- Remdesivir (37)
- Repurposing (2)
- Respiratory-Disease (3)
- Right-to-Try (3)
- Risk-Sharing-Agreements (2)
- RWD (2)
- RWE (2)
- Sackler-Family (28)
- Safe-Importation (2)
- Safety-Standards (9)
- Senate-Hearings (20)
- Shkreli (11)
- Sickle-Cell-Disease (2)
- Side-Effects (2)
- Single-Payer (21)
- SMA (3)
- Smoking (2)
- SOTU (5)
- Sovaldi (3)
- Specialty-Drugs (4)
- Spinal-Muscular-Atrophy (7)
- Spinraza (4)
- State-level (110)
- Step-Therapy (3)
- Stock-Market (2)
- Supply-Chain (9)
- Tariffs (3)
- Tax-Credits (3)
- TB (4)
- Thalidomide (3)
- Theranos (2)
- Top-10 (2)
- Trade (22)
- Treatment-Cost (3)
- TRIPS (2)
- Trump (227)
- Trump (379 (3)
- Tuberculosis (3)
- TV-Ads (30)
- UK-Politics (6)
- Uninsured (2)
- Universal-Healthcare (20)
- US-Insurers (59)
- US-Policy (59)
- US-Politics (154)
- USMCA (9)
- Vaccinations (35)
- Vaccine-Access (11)
- Vaccine-Deal (5)
- Vaccine-Development (2)
- Vaccine-Diplomacy (11)
- Vaccine-Distribution (37)
- Vaccine-Efficacy (3)
- Vaccine-Nationalism (7)
- Vaccine-Passport (3)
- Vaccine-Pricing (11)
- Vaccine-Programs (2)
- Vaccine-Rollout (30)
- Vaccine-Supply (21)
- Vaccines (274)
- Value-Based-Medicine (2)
- Value-based Contracts (6)
- Value-based Payment (12)
- Value-based Pricing (32)
- Value-in-Health (9)
- Value-of-Medicines (3)
- Vaping (2)
- Vincristine (5)
- Viral-Mutations (7)
- Viral-Strain (9)
- Wall-St (4)
- Wealth-Distribution (2)
- Whistleblowers (2)
- WHO (13)
- Zantac (3)
- Zolgensma (6)
Videos
close
- Reset All Filters
- 1 result found
- x Plans-for-Kids
-
Private Coverage Often Isn't Enough For Children
Often, private coverage is assumed to be better than public coverage. More and more often, that’s just not what families are finding.
Comments